Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016

Abstract

While XDR-GC are currently rare in Canada, MDR-GC have increased over the last five years. Azithromycin resistance in <i>N. gonorrhoeae</i> is established and spreading in Canada, exceeding the 5% level at which the World Health Organization states an antimicrobial should be reviewed as an appropriate treatment. Continued surveillance of antimicrobial susceptibilities of <i>N. gonorrhoeae</i> is necessary to inform treatment guidelines and mitigate the impact of resistant gonorrhea.